









市場行情
/
股票
/
nasdaq-ikt
/

Inhibikase Therapeutics Inc

IKT

1.645USD

-0.075-4.36%

交易中（美東）報價延遲15分鐘

123.06M總市值

3.49本益比TTM



Inhibikase Therapeutics Inc

1.645

-0.075-4.36%

概覽公司財務分析

概覽

公司

財務

分析

關於 Inhibikase Therapeutics Inc 公司

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Inhibikase Therapeutics Inc簡介



公司代碼IKT

公司名稱Inhibikase Therapeutics Inc

上市日期Dec 23, 2020

CEOIwicki (Mark T)

員工數量15

證券類型Ordinary Share

年結日Dec 23

公司地址1000 N. West Street, Suite 1200

城市WILMINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編19801

電話13022953800

網址https://www.inhibikase.com/

公司代碼IKT

上市日期Dec 23, 2020

CEOIwicki (Mark T)

Inhibikase Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Roberto Bellini

Independent Director

1.46M

Mr. Vincent E. (Vince) Aurentz

Independent Director

893.54K

Mr. Amit D. Munshi

Independent Chairman of the Board

431.81K

Mr. Arvind Kush

Independent Director

145.00K

Mr. David Mcintyre

Chief Financial Officer, Principal Accounting Officer

10.29K

Dr. John Adams, Ph.D.

Chief Scientific Officer

Mr. Timothy (Tim) Pigot

Chief Commercial and Strategy Officer

Mr. Dennis N. Berman

Independent Director

Dr. Roy Freeman, M.D.

Independent Director

Mr. Mike Moyer

Managing Director of LifeSci Advisors

名稱

名稱/職務

職務

持股

持股變動

Mr. Roberto Bellini

Independent Director

1.46M

Mr. Vincent E. (Vince) Aurentz

Independent Director

893.54K

Mr. Amit D. Munshi

Independent Chairman of the Board

431.81K

Mr. Arvind Kush

Independent Director

145.00K

Mr. David Mcintyre

Chief Financial Officer, Principal Accounting Officer

10.29K

Dr. John Adams, Ph.D.

Chief Scientific Officer

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月15日週六

持股股東

股東類型

持股股東

佔比

Sands Capital Ventures LLC

10.77%

Soleus Capital Management, L.P.

5.23%

Fairmount Funds Management LLC

5.07%

SP IKT Holdings LLC

4.83%

Perceptive Advisors LLC

4.48%

其他

69.62%

持股股東

佔比

Sands Capital Ventures LLC

10.77%

Soleus Capital Management, L.P.

5.23%

Fairmount Funds Management LLC

5.07%

SP IKT Holdings LLC

4.83%

Perceptive Advisors LLC

4.48%

其他

69.62%

股東類型

持股股東

佔比

Hedge Fund

31.76%

Investment Advisor

5.84%

Investment Advisor/Hedge Fund

4.85%

Corporation

4.83%

Private Equity

4.48%

Individual Investor

3.18%

Research Firm

0.24%

Bank and Trust

0.06%

Pension Fund

0.04%

其他

44.72%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

110

54.77M

73.50%

+878.44K

2025Q2

62.36M

83.88%

+6.72M

2025Q1

60.21M

81.40%

+7.53M

2024Q4

58.78M

83.36%

+15.59M

2024Q3

1.99M

24.34%

-203.16K

2024Q2

2.13M

28.26%

+379.22K

2024Q1

1.51M

21.65%

-625.47K

2023Q4

1.53M

25.68%

-638.36K

2023Q3

2.02M

35.52%

-749.23K

2023Q2

2.34M

41.60%

-408.30K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Sands Capital Ventures LLC

10.95M

14.69%

Jun 30, 2025

Soleus Capital Management, L.P.

6.33M

8.49%

Jun 30, 2025

Fairmount Funds Management LLC

6.13M

8.22%

Jun 30, 2025

SP IKT Holdings LLC

5.84M

7.84%

+5.84M

Oct 21, 2024

Perceptive Advisors LLC

5.43M

7.29%

-492.71K

-8.32%

Jun 30, 2025

Commodore Capital LP

5.40M

7.24%

+53.06K

+0.99%

Jun 30, 2025

Adar1 Capital Management LLC

5.12M

6.87%

Jun 30, 2025

The Vanguard Group, Inc.

3.22M

4.33%

+375.71K

+13.19%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.43M

3.25%

+2.08M

+608.12%

Jun 30, 2025

Blackstone Alternative Asset Management, L.P.

2.64M

3.54%

+567.59K

+27.41%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

iShares Russell 2000 Growth ETF

Global X Russell 2000 ETF

Proshares Ultra Russell 2000

ProShares UltraPro Russell2000

iShares Micro-Cap ETF

佔比0.02%

iShares Russell 2000 Value ETF

佔比0.01%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

Global X Russell 2000 ETF

佔比0%

Proshares Ultra Russell 2000

佔比0%

ProShares UltraPro Russell2000

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

公告日期

類型

比率

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

常見問題

Inhibikase Therapeutics Inc的前五大股東是誰？



Inhibikase Therapeutics Inc的前五大股東如下：
Sands Capital Ventures LLC
持有股份：10.95M
佔總股份比例：14.69%。
Soleus Capital Management, L.P.
持有股份：6.33M
佔總股份比例：8.49%。
Fairmount Funds Management LLC
持有股份：6.13M
佔總股份比例：8.22%。
SP IKT Holdings LLC
持有股份：5.84M
佔總股份比例：7.84%。
Perceptive Advisors LLC
持有股份：5.43M
佔總股份比例：7.29%。